Phathom Pharmaceuticals (PHAT) Capital Expenditures (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has 8 years of Capital Expenditures data on file, last reported at $61000.0 in Q1 2026.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $61000.0 in Q1 2026; TTM through Mar 2026 was $1.3 million, a 4115.62% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, up 15200.0% from the prior year.
• Capital Expenditures for Q1 2026 stood at $61000.0, down from $1.2 million in the prior quarter.
• Over the last five years, Capital Expenditures for PHAT reached as high as $3.4 million in Q3 2023 and fell as low as -$2.1 million in Q4 2023.
• Historically, Capital Expenditures has averaged $200357.1 across 5 years, with a median of $50500.0 in 2024.
• On a YoY basis, Capital Expenditures climbed as much as 1126.0% in 2022 and fell as far as 1235.56% in 2022.
• Year by year, Capital Expenditures stood at -$511000.0 in 2022, then tumbled by 302.35% to -$2.1 million in 2023, then soared by 94.07% to -$122000.0 in 2024, then jumped by 1061.48% to $1.2 million in 2025, then tumbled by 94.8% to $61000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $61000.0 in Q1 2026, $1.2 million in Q4 2025, and -$64000.0 in Q3 2025.